Lead Product(s): Soticlestat
Therapeutic Area: Neurology Product Name: TAK-935
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Ovid Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Primary endpoint achieved, demonstrating a statistically significant reduction of seizures from baseline compared to placebo in the combined Dravet syndrome and Lennox-Gastaut syndrome study population.